Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aslan Pharmaceuticals Ltd ADR (ASLN)

Aslan Pharmaceuticals Ltd ADR (ASLN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,941
  • Shares Outstanding, K 32,050
  • Annual Sales, $ 3,000 K
  • Annual Income, $ -47,070 K
  • 60-Month Beta 2.80
  • Price/Sales 10.79
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.63
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/04/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.12
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8300 +16.31%
on 03/19/20
2.2000 -56.12%
on 03/06/20
-0.9146 (-48.65%)
since 03/03/20
3-Month
0.8300 +16.31%
on 03/19/20
2.8500 -66.13%
on 01/17/20
-1.1946 (-55.31%)
since 01/03/20
52-Week
0.3500 +175.83%
on 11/14/19
8.1800 -88.20%
on 12/02/19
-3.1346 (-76.45%)
since 04/03/19

Most Recent Stories

More News
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: What Does It Mean for the Stock?

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ASLN : 0.9654 (-4.41%)
ASLAN Pharmaceuticals Ltd. (ASLN) Gains But Lags Market: What You Should Know

ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.17, moving +0.93% from the previous trading session.

ASLN : 0.9654 (-4.41%)
Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA

The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.

SNY : 44.83 (+3.03%)
REGN : 493.32 (-1.09%)
ALNY : 105.82 (+1.54%)
ASLN : 0.9654 (-4.41%)
Has ASLAN Pharmaceuticals (ASLN) Outpaced Other Medical Stocks This Year?

Is (ASLN) Outperforming Other Medical Stocks This Year?

ASLN : 0.9654 (-4.41%)
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.

ALXN : 89.77 (-0.64%)
CLSN : 0.8868 (-2.55%)
AVXL : 2.62 (-0.38%)
ASLN : 0.9654 (-4.41%)
Momenta (MNTA) Provides Pipeline Updates, Stock Rallies

Shares of Momenta (MNTA) rise 23.7% on pipeline updates.

ALXN : 89.77 (-0.64%)
MNTA : 24.19 (-0.29%)
CLSN : 0.8868 (-2.55%)
ASLN : 0.9654 (-4.41%)
Ultragenyx Provides Preliminary Crysvita 2019 Revenues

Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.

RARE : 48.30 (-3.44%)
CLSN : 0.8868 (-2.55%)
ALXN : 89.77 (-0.64%)
ASLN : 0.9654 (-4.41%)
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

ASLN : 0.9654 (-4.41%)
Is ASLAN Pharmaceuticals (ASLN) Outperforming Other Medical Stocks This Year?

Is (ASLN) Outperforming Other Medical Stocks This Year?

ASLN : 0.9654 (-4.41%)
Will ASLAN Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in ASLAN Pharmaceuticals.

ASLN : 0.9654 (-4.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ASLN with:

Business Summary

ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003...

See More

Key Turning Points

2nd Resistance Point 1.0583
1st Resistance Point 1.0118
Last Price 0.9654
1st Support Level 0.9171
2nd Support Level 0.8689

See More

52-Week High 8.1800
Fibonacci 61.8% 5.1889
Fibonacci 50% 4.2650
Fibonacci 38.2% 3.3411
Last Price 0.9654
52-Week Low 0.3500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar